Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer
IntroductionProgrammed death-ligand 1 (PD-L1) blockade is a growing treatment for extensive-stage small cell lung cancer (ES-SCLC). This study evaluates the cost-effectiveness of benmelstobart and anlotinib plus etoposide/carboplatin (EC) compared versus anlotinib plus EC and EC alone for patients w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1524108/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329557254963200 |
|---|---|
| author | Jing Nie Conghui Kou Ke Tang Siyu Dai Xifeng Zhao Jiyong Wu |
| author_facet | Jing Nie Conghui Kou Ke Tang Siyu Dai Xifeng Zhao Jiyong Wu |
| author_sort | Jing Nie |
| collection | DOAJ |
| description | IntroductionProgrammed death-ligand 1 (PD-L1) blockade is a growing treatment for extensive-stage small cell lung cancer (ES-SCLC). This study evaluates the cost-effectiveness of benmelstobart and anlotinib plus etoposide/carboplatin (EC) compared versus anlotinib plus EC and EC alone for patients with ES-SCLC in China.MethodsUsing a Markov model over 5-year boundary and data from the ETER701 trials, we analyzed quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), total cost, incremental net health benefit (INHB) and incremental monetary benefit (INMB). To address uncertainties, we conducted one-way analysis and probabilistic sensitivity analysis (PSA). Scenario analyses were used to evaluate the resilience of our model's findings.ResultsThe administration of triple therapy for ES-SCLC demonstrated a significant improvement in QALY, with respective gains of 0.26, 0.39, compared with the other two schemes. However, enhanced therapeutic benefit was accompanied by increased costs. And triple therapy showed less cost-effectiveness with ICER of $189797.99 and $149249.24 per QALY respectively when compared with other schemes. Moreover, the analysis revealed an INHB of −1.04, −1.12 QALYs, and the INMB of −39755.48 $, −42819.93 $ respectively. Sensitivity analysis demonstrated that benmelstobart's cost was the main driver of cost-effectiveness. The cost-effectiveness acceptability curve displayed that the likelihood of triple therapy being cost-effective increased from 34.20% to 97.60% when the threshold value for cost per QALY gained varied from $180000 to $240000. The scenario analysis supported these findings.DiscussionTriple therapy was a less cost-effective option for patients with ES-SCLC compared with anlotinib plus EC and EC alone in China. |
| format | Article |
| id | doaj-art-a8d8d74935754307934ee4c9e69dfa32 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-a8d8d74935754307934ee4c9e69dfa322025-08-20T03:47:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-08-011610.3389/fphar.2025.15241081524108Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancerJing Nie0Conghui Kou1Ke Tang2Siyu Dai3Xifeng Zhao4Jiyong Wu5Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, ChinaDepartment of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, ChinaCollege of Pharmacy, Linyi University, Linyi, Shandong, ChinaCollege of Pharmacy, Shandong Medical College, Jinan, Shandong, ChinaCollege of Pharmacy, Shandong Medical College, Jinan, Shandong, ChinaDepartment of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, ChinaIntroductionProgrammed death-ligand 1 (PD-L1) blockade is a growing treatment for extensive-stage small cell lung cancer (ES-SCLC). This study evaluates the cost-effectiveness of benmelstobart and anlotinib plus etoposide/carboplatin (EC) compared versus anlotinib plus EC and EC alone for patients with ES-SCLC in China.MethodsUsing a Markov model over 5-year boundary and data from the ETER701 trials, we analyzed quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), total cost, incremental net health benefit (INHB) and incremental monetary benefit (INMB). To address uncertainties, we conducted one-way analysis and probabilistic sensitivity analysis (PSA). Scenario analyses were used to evaluate the resilience of our model's findings.ResultsThe administration of triple therapy for ES-SCLC demonstrated a significant improvement in QALY, with respective gains of 0.26, 0.39, compared with the other two schemes. However, enhanced therapeutic benefit was accompanied by increased costs. And triple therapy showed less cost-effectiveness with ICER of $189797.99 and $149249.24 per QALY respectively when compared with other schemes. Moreover, the analysis revealed an INHB of −1.04, −1.12 QALYs, and the INMB of −39755.48 $, −42819.93 $ respectively. Sensitivity analysis demonstrated that benmelstobart's cost was the main driver of cost-effectiveness. The cost-effectiveness acceptability curve displayed that the likelihood of triple therapy being cost-effective increased from 34.20% to 97.60% when the threshold value for cost per QALY gained varied from $180000 to $240000. The scenario analysis supported these findings.DiscussionTriple therapy was a less cost-effective option for patients with ES-SCLC compared with anlotinib plus EC and EC alone in China.https://www.frontiersin.org/articles/10.3389/fphar.2025.1524108/fullextensive-stage small-cell lung cancerbenmelstobartanlotinibcarboplatinetoposidecost-effectiveness |
| spellingShingle | Jing Nie Conghui Kou Ke Tang Siyu Dai Xifeng Zhao Jiyong Wu Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer Frontiers in Pharmacology extensive-stage small-cell lung cancer benmelstobart anlotinib carboplatin etoposide cost-effectiveness |
| title | Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer |
| title_full | Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer |
| title_fullStr | Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer |
| title_full_unstemmed | Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer |
| title_short | Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer |
| title_sort | cost effectiveness evaluation of benmelstobart anlotinib and chemotherapy in patients with extensive stage small cell lung cancer |
| topic | extensive-stage small-cell lung cancer benmelstobart anlotinib carboplatin etoposide cost-effectiveness |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1524108/full |
| work_keys_str_mv | AT jingnie costeffectivenessevaluationofbenmelstobartanlotinibandchemotherapyinpatientswithextensivestagesmallcelllungcancer AT conghuikou costeffectivenessevaluationofbenmelstobartanlotinibandchemotherapyinpatientswithextensivestagesmallcelllungcancer AT ketang costeffectivenessevaluationofbenmelstobartanlotinibandchemotherapyinpatientswithextensivestagesmallcelllungcancer AT siyudai costeffectivenessevaluationofbenmelstobartanlotinibandchemotherapyinpatientswithextensivestagesmallcelllungcancer AT xifengzhao costeffectivenessevaluationofbenmelstobartanlotinibandchemotherapyinpatientswithextensivestagesmallcelllungcancer AT jiyongwu costeffectivenessevaluationofbenmelstobartanlotinibandchemotherapyinpatientswithextensivestagesmallcelllungcancer |